Eileen Marshall

Cooley advised LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including schizophrenia, on its $285 million upsized initial public offering (IPO).

Cooley advised Uber Technologies (NYSE: UBER), a technology platform that uses a massive network, leading technology, operational excellence and product expertise to power movement from point A to point B, on its $2.25 billion investment-grade bond offering.

Cooley advised Thirty Madison, a specialty healthcare company offering high-quality virtual specialized care for patients experiencing a range of conditions, on its definitive agreement to be acquired by Remedy Meds in an all-stock transaction valued in excess of $500 million.

Cooley advised DigitalOcean Holdings (NYSE: DOCN), a simple, scalable cloud platform that democratizes cloud and artificial intelligence for digital native enterprises around the world, on its $625 million aggregate principal amount of convertible senior notes due 2030 in a private offering pursuant to Rule 144A under the Securities Act of 1933, including the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of the notes.